Final coverage decision for some Alzheimer's drugs is almost here: What to remember and what to expect
The wait is almost over.
The Centers for Medicare and Medicaid Services sometime in the next few days will finally offer its ultimate decision on whether to pay for Biogen’s controversial Alzheimer’s drug and others that might target the sticky plaques known as amyloids — a costly expenditure to be sure — even as the drugs have so far failed to establish a clinical benefit.
Some background: In January, several months after Biogen’s R&D chief Al Sandrock jumped ship, and not for retirement, CMS released its draft decision saying that, starting in 90 days, it will only pay for Biogen’s Aduhelm and other FDA-approved anti-amyloid monoclonal antibodies for Alzheimer’s disease under CMS-approved randomized controlled trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
